Elevance Health (NYSE:ELV) and biote (NASDAQ:BTMD) Head-To-Head Analysis

biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

21.7% of biote shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 0.3% of Elevance Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

biote has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Elevance Health has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares biote and Elevance Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	3.19%	-22.33%	12.10%
Elevance Health	2.47%	14.64%	5.22%

Valuation and Earnings

This table compares biote and Elevance Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$183.53 million	0.22	$27.05 million	$0.11	10.37
Elevance Health	$199.12 billion	0.44	$5.66 billion	$22.50	17.93

Elevance Health has higher revenue and earnings than biote. biote is trading at a lower price-to-earnings ratio than Elevance Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for biote and Elevance Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1	1	1	1	2.50
Elevance Health	0	8	15	0	2.65

biote currently has a consensus price target of $2.50, suggesting a potential upside of 119.11%. Elevance Health has a consensus price target of $441.48, suggesting a potential upside of 9.46%. Given biote’s higher possible upside, analysts clearly believe biote is more favorable than Elevance Health.

Summary

Elevance Health beats biote on 9 of the 15 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Elevance Health

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.